Thierry Van Nieuwenhove
Chief Executive Officer
Thierry Van Nieuwenhove joined Quotient Sciences in October 2023. Thierry has an extensive track record in the pharma/CDMO services industry spanning over 23 years and with experience in both small molecules and biologics.
Thierry joins us from ABL Inc. where he was the Chief Executive Officer for the last two years. Prior to this, he held various senior leadership roles in the CDMO industry, including as the President of the Synthesis business unit at Novasep, Global Head of Business Development at Lonza, and CEO of Minakem, the CDMO and API manufacturing division of Minafin Group.
On joining, Thierry Van Nieuwenhove said: "I am honoured to join Quotient Sciences as its new CEO and lead a team dedicated to improving the lives of patients worldwide. I have admired the company’s strong development in recent years, building a global footprint and bringing its innovative Translational Pharmaceutics® delivery platform to customers across the world. I’m grateful for the opportunity and looking forward to driving the business through its next phase of growth, and continuing the team’s desire to accelerate the development of new medicines.”
Thierry succeeds Mark Egerton who, after 18 years of successfully leading Quotient Sciences as CEO, has retired.
SVP & Chief Financial Officer
Des has significant experience as a CFO in both private and public companies.
Wayne Hewett is an industry veteran and dedicated Senior Advisor to Permira, bringing more than three decades of board and leadership experience to Quotient Sciences. Wayne presently serves as Chairman of Cambrex, a global CDMO, and sits as part of the Board of Directors for companies including The Home Depot, Wells Fargo, UPS, and Lytx.
Dimitrios focuses on investment opportunities in the Healthcare sector.
Prior to joining Permira, he worked for Onex for three years, where he was in charge of Healthcare investments in Europe. Prior to that, he spent nine years with BC Partners.
Dimitrios holds a Master of Science in Corporate Finance from Bocconi University, Italy, and has an MBA from Harvard Business School, USA.
Henry focuses on investment opportunities in the Healthcare sector and has worked on numerous transactions including Atrium, BakerCorp, Cambrex, Genesys, Intelligrated, Intelsat, Jet Aviation and LSNE.
Prior to joining Permira, Henry spent five years at The Cypress Group, a US private equity firm, where he completed a number of buy-out transactions. He has also worked at Salomon Brothers in the investment banking division and in the Distressed Debt group of LibertyView Capital Management, a multi-strategy hedge fund.
Henry has a degree in Finance from Georgetown University, USA, and an MBA from Harvard Business School, USA.
Domitille de Vienne
Domitille de Vienne focuses on investment opportunities in the Healthcare sector at Permira and has more than a decade of experience working in the Healthcare investment space. Prior to joining Permira in 2022, she worked at CDPQ as part of the direct private equity team, where she was in charge of healthcare investments in Europe. Domitille holds a degree in Corporate Finance and Business from ESCP Business School, France.